The SynchroMed II Implantable and SynchroMed EL Implantable infusion pumps may stall intermittently or completely halt, which can interrupt medications being delivered.
The only drugs approved for use with these pumps are morphine, baclofen, ziconotide, floxuridine and methotrexate. Drugs not approved increase the failure rate of the device from 2.4 percent to 7 percent.
More Articles on Devices:
Omeros Shares Drop 9% After Knee Surgery Clinical Trial Results Released
Aspen Valley Hospital Acquires MAKOplasty Robotic System
Wood May be Suitable Bone Replacement in Orthopedic Implants
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
